Company profile: Global Blood Therapeutics
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapies for sickle cell disease, including Oxbryta, which increases hemoglobin levels and reduces hemolysis, and voxelotor, an oral, once-daily therapy that increases hemoglobin's affinity for oxygen to reduce red blood cell sickling.
Products and services
- Voxelotor: Oral, once-daily therapy candidate that increases hemoglobin’s oxygen affinity to reduce red blood cell sickling, targeting sickle cell disease pathophysiology
- Oxbryta: Biopharmaceutical medication engineered to treat sickle cell disease by elevating hemoglobin levels and reducing hemolysis via targeted hemoglobin modulation
- Innovative Treatment Development: Clinical-stage biopharmaceutical program that discovers, develops, and delivers therapies for underserved patient communities, emphasizing an oral, once-daily sickle cell disease therapy
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Global Blood Therapeutics
Minoryx Therapeutics
HQ: Spain
Website
- Description: Provider of pharmacological chaperone small-molecule drugs for genetic, neurometabolic, and rare pediatric diseases. Develops leriglitazone, a selective PPAR gamma agonist for X-linked adrenoleukodystrophy and other CNS diseases, supported by phase 2/3 results. Programs include ADVANCE (adult X-ALD), NEXUS (pediatric cALD), CALYX (adult progressive cALD), and a Friedreich's ataxia proof-of-concept.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Minoryx Therapeutics company profile →
Eidos Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biotechnology research and development of novel, genetically targeted therapies to improve the lives of patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eidos Therapeutics company profile →
Essentialis Therapeutics
HQ: United States
Website
- Description: Provider of orphan drug-focused pharmaceutical research and development, based in Carlsbad, in a clinical trial phase to develop breakthrough medicines for the treatment of rare metabolic diseases where there is increased mortality and risk of cardiovascular and endocrine.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Essentialis Therapeutics company profile →
Comet Therapeutics
HQ: United States
Website
- Description: Provider of therapies designed to treat orphan neurological disorders; develops treatments to restore dysregulated CoEnzyme A metabolism through a CoEnzyme metabolism platform, enabling physicians to address profound unmet medical needs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Comet Therapeutics company profile →
uniQure
HQ: The Netherlands
Website
- Description: Provider of gene-based therapies focused on research and early development. Offerings include AMT-130 for Huntington’s disease, Etranacogene Dezaparvovec for severe or moderately severe Hemophilia B, AMT-260 for refractory temporal lobe epilepsy, AAV-miQURE targeting ALS C9orf72 transcripts, and the linQURE platform for multi-transcript targeting; a leader that developed the first and only EU-approved gene therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full uniQure company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Global Blood Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Global Blood Therapeutics
2.2 - Growth funds investing in similar companies to Global Blood Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Global Blood Therapeutics
4.2 - Public trading comparable groups for Global Blood Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →